Analysis of HCV Genotype 1 Variants Detected During Monotherapy and Combination Therapy With Next Generation HCV Direct-Acting Anti viral Agents ABT-493 and ABT-530 "........COMBINATION THERAPY (SURVEYOR-I PART 1, PHASE 2 DOSE-RANGING STUDY) .....All patients with baseline NS3 or NS5A variants achieved SVR12 (Study SVR12: 99%)"

Conference Reports for NATAP

66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015


Analysis of HCV Genotype 1 Variants Detected During Monotherapy and Combination Therapy With Next Generation HCV Direct-Acting Anti viral Agents ABT-493 and ABT-530 "........COMBINATION THERAPY (SURVEYOR-I PART 1, PHASE 2 DOSE-RANGING STUDY) .....All patients with baseline NS3 or NS5A variants achieved SVR12 (Study SVR12: 99%)"

	Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco, CA Teresa Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Tanya Dekhtyar, Armen Asatryan, Federico Mensa, Andrew Campbell, Jens Kort, Christine Collins AbbVie Inc., North Chicago, Illinois, United States